Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 6Terminated 4Unknown 2Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 10Recurrence 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Lymphoma, T-Cell, Peripheral 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Hematologic Neoplasms 2Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myeloid 1Glioma 1Frailty 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 55Cyclophosphamide 38Vincristine 25Prednisone 24Doxorubicin 21Cytarabine 18Etoposide 17Lenalidomide 16Gemcitabine 12Melphalan 8Filgrastim 8Cisplatin 8Peripheral Blood Stem Cell Transplantation 7Oxaliplatin 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7Methotrexate 7Ifosfamide 7Carmustine 7zanubrutinib 6R-CHOP protocol 6Vindesine 5Radiotherapy 5Dexamethasone 5Busulfan 5ibrutinib 4fludarabine phosphate 4Methylprednisolone 4Epirubicin 4Decitabine 4Cyclosporine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Lymphoma, Large B-Cell, Diffuse × Azacitidine × Clear all
NCT05823701 2023-04-21

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

The First Affiliated Hospital of Soochow University

Phase 2 Unknown
23 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03719989 2018-10-25

EPIC

Seoul National University Hospital

Phase 2 Unknown
27 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡